Wallace Akerley

27.3k total citations
156 papers, 5.2k citations indexed

About

Wallace Akerley is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Wallace Akerley has authored 156 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Pulmonary and Respiratory Medicine, 104 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Wallace Akerley's work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (37 papers) and Lung Cancer Diagnosis and Treatment (34 papers). Wallace Akerley is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (37 papers) and Lung Cancer Diagnosis and Treatment (34 papers). Wallace Akerley collaborates with scholars based in United States, Italy and Germany. Wallace Akerley's co-authors include Howard Safran, Bernard F. Cole, William W. Mayo-Smith, Ronald J. Zagoria, Peter V. Kavanagh, Damian E. Dupuy, Michael Glantz, H. Choy, Joachim von Pawel and James E. Herndon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Wallace Akerley

149 papers receiving 5.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Wallace Akerley 3.1k 2.7k 1.1k 515 496 156 5.2k
Shenhong Wu 1.7k 0.5× 2.9k 1.1× 1.4k 1.3× 424 0.8× 351 0.7× 96 5.5k
Mark Kozloff 1.7k 0.5× 3.2k 1.2× 1.3k 1.2× 612 1.2× 454 0.9× 125 4.7k
Patrick M. Forde 2.7k 0.9× 4.0k 1.5× 934 0.9× 501 1.0× 161 0.3× 186 5.7k
Ronald L. Burkes 3.7k 1.2× 4.2k 1.6× 683 0.6× 720 1.4× 487 1.0× 95 6.0k
Philip Bonomi 4.4k 1.4× 4.9k 1.8× 2.1k 1.9× 648 1.3× 274 0.6× 241 8.0k
Bernhard C. Pestalozzi 1.7k 0.5× 2.9k 1.1× 598 0.6× 1.1k 2.1× 555 1.1× 107 4.6k
Ashley E. Winkler 2.5k 0.8× 3.9k 1.4× 1.1k 1.1× 1.4k 2.7× 570 1.1× 12 7.3k
Rogério Lilenbaum 5.5k 1.7× 5.6k 2.1× 2.1k 2.0× 473 0.9× 374 0.8× 105 8.4k
Wilfried Eberhardt 5.3k 1.7× 4.2k 1.5× 1.7k 1.5× 559 1.1× 270 0.5× 239 7.6k
Alessandra Bearz 3.1k 1.0× 2.5k 0.9× 772 0.7× 369 0.7× 146 0.3× 176 4.4k

Countries citing papers authored by Wallace Akerley

Since Specialization
Citations

This map shows the geographic impact of Wallace Akerley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wallace Akerley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wallace Akerley more than expected).

Fields of papers citing papers by Wallace Akerley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wallace Akerley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wallace Akerley. The network helps show where Wallace Akerley may publish in the future.

Co-authorship network of co-authors of Wallace Akerley

This figure shows the co-authorship network connecting the top 25 collaborators of Wallace Akerley. A scholar is included among the top collaborators of Wallace Akerley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wallace Akerley. Wallace Akerley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sinnott, Jennifer A., et al.. (2023). Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer. Cancer Treatment and Research Communications. 35. 100686–100686. 3 indexed citations
2.
Gadgeel, Shirish M., Jieling Miao, Jonathan W. Riess, et al.. (2023). Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042). Clinical Cancer Research. 29(18). 3641–3649. 9 indexed citations
3.
Cannon‐Albright, Lisa, Craig C. Teerlink, Jeff Stevens, et al.. (2023). A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall‐cell lung cancer. International Journal of Cancer. 153(2). 364–372. 1 indexed citations
4.
Barnard, Mollie E., et al.. (2023). Pathways to lung cancer diagnosis among individuals who did not receive lung cancer screening: a qualitative study. BMC Primary Care. 24(1). 203–203. 4 indexed citations
5.
Yang, James Chih‐Hsin, Karen L. Reckamp, Young‐Chul Kim, et al.. (2020). Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports. 2(2). 100114–100114. 19 indexed citations
6.
Akerley, Wallace, et al.. (2019). Public awareness and perceptions surrounding radon testing in a state with high radon emission potential and low smoking rates.. Journal of environmental health. 82(3). 8–17. 5 indexed citations
7.
Cannon‐Albright, Lisa, Shamus R. Carr, & Wallace Akerley. (2019). Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer. Journal of Thoracic Oncology. 14(7). 1184–1191. 32 indexed citations
8.
Goldberg, Michael E., Meagan Montesion, Lauren Young, et al.. (2018). Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE. 13(11). e0208097–e0208097. 15 indexed citations
9.
Chalmers, A., et al.. (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. The Oncologist. 24(7). 963–972. 19 indexed citations
10.
Scagliotti, Giorgio V., Dale E. Shuster, С. В. Орлов, et al.. (2017). Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. Journal of Thoracic Oncology. 13(6). 849–854. 37 indexed citations
11.
Nemunaitis, John, Hossein Borghaei, Wallace Akerley, et al.. (2017). P2.06-014 Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy. Journal of Thoracic Oncology. 12(1). S1078–S1078. 3 indexed citations
12.
Serwatowski, Piotr, Aleksandra Szczęsna, Joachim von Pawel, et al.. (2017). P3.02b-045 Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non–Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study. Journal of Thoracic Oncology. 12(1). S1214–S1215. 9 indexed citations
13.
14.
Gurevich, Irina & Wallace Akerley. (2001). Treatment of the jaundiced patient with breast carcinoma. Cancer. 91(4). 660–663. 5 indexed citations
15.
Gurevich, Irina & Wallace Akerley. (2001). Treatment of the jaundiced patient with breast carcinoma. Cancer. 91(4). 660–663. 1 indexed citations
16.
Stein, Barry S., et al.. (1997). Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer. Mayo Clinic Proceedings. 72(10). 932–934. 1 indexed citations
17.
Akerley, Wallace, et al.. (1997). Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer. Mayo Clinic Proceedings. 72(10). 932–934. 9 indexed citations
18.
Glantz, Michael, H. Choy, Wallace Akerley, et al.. (1997). Weekly paclitaxel with and without concurrent radiation therapy: Toxicity, pharmacokinetics, and response. Seminars in Radiation Oncology. 7. 7 indexed citations
19.
Akerley, Wallace, et al.. (1997). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.. PubMed. 24(5 Suppl 17). S17–90. 28 indexed citations
20.
Choy, H., et al.. (1996). Concurrent Paclitaxel and Radiation Therapy for Solid Tumors. Cancer Control. 3(4). 310–318. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shenhong Wu Breakdown of academic impact, for papers by Mark Kozloff Breakdown of academic impact, for papers by Patrick M. Forde Breakdown of academic impact, for papers by Ronald L. Burkes Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Bernhard C. Pestalozzi Breakdown of academic impact, for papers by Ashley E. Winkler Breakdown of academic impact, for papers by Rogério Lilenbaum Breakdown of academic impact, for papers by Wilfried Eberhardt Breakdown of academic impact, for papers by Alessandra Bearz
Rankless by CCL
2026